{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Oral+ritonavir&page=2",
    "query": {
      "intervention": "Oral ritonavir",
      "page": 2
    },
    "page_size": 10
  },
  "pagination": {
    "page": 2,
    "page_size": 10,
    "total_count": 164,
    "total_pages": 17,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Oral+ritonavir&page=3&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Oral+ritonavir&page=1&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-02T15:25:27.395Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT00646776",
      "title": "Drug Interaction Study",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Antivirals/HIV"
      ],
      "interventions": [
        {
          "name": "Rifabutin",
          "type": "DRUG"
        },
        {
          "name": "Rifabutin + Atazanavir + Ritonavir",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Bristol-Myers Squibb",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "50 Years",
        "sex": "ALL",
        "summary": "18 Years to 50 Years"
      },
      "enrollment_count": 85,
      "start_date": "2008-04",
      "completion_date": "2008-08",
      "has_results": true,
      "last_update_posted_date": "2013-01-31",
      "last_synced_at": "2026-10-02T15:25:27.395Z",
      "location_count": 1,
      "location_summary": "Hamilton, New Jersey",
      "locations": [
        {
          "city": "Hamilton",
          "state": "New Jersey"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00646776"
    },
    {
      "nct_id": "NCT00096850",
      "title": "Safety, Tolerability, and Blood Levels of Ritonavir-Boosted Atazanavir and Rifampin When Taken Together in HIV Uninfected Adults",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "HIV Infections",
        "Tuberculosis"
      ],
      "interventions": [
        {
          "name": "Atazanavir",
          "type": "DRUG"
        },
        {
          "name": "Rifampin",
          "type": "DRUG"
        },
        {
          "name": "Ritonavir",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)",
      "sponsor_class": "NIH",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 18,
      "start_date": null,
      "completion_date": "2007-12",
      "has_results": false,
      "last_update_posted_date": "2021-11-01",
      "last_synced_at": "2026-10-02T15:25:27.395Z",
      "location_count": 3,
      "location_summary": "Palo Alto, California • Columbus, Ohio • Nashville, Tennessee",
      "locations": [
        {
          "city": "Palo Alto",
          "state": "California"
        },
        {
          "city": "Columbus",
          "state": "Ohio"
        },
        {
          "city": "Nashville",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00096850"
    },
    {
      "nct_id": "NCT05011513",
      "title": "Evaluation of Protease Inhibition for COVID-19 in Standard-Risk Patients (EPIC-SR).",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2",
        "PHASE3"
      ],
      "conditions": [
        "COVID-19"
      ],
      "interventions": [
        {
          "name": "PF-07321332",
          "type": "DRUG"
        },
        {
          "name": "Ritonavir",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Pfizer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 1440,
      "start_date": "2021-08-25",
      "completion_date": "2022-07-25",
      "has_results": true,
      "last_update_posted_date": "2023-08-14",
      "last_synced_at": "2026-10-02T15:25:27.395Z",
      "location_count": 78,
      "location_summary": "Pelham, Alabama • Mesa, Arizona • Scottsdale, Arizona + 51 more",
      "locations": [
        {
          "city": "Pelham",
          "state": "Alabama"
        },
        {
          "city": "Mesa",
          "state": "Arizona"
        },
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Canoga Park",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05011513"
    },
    {
      "nct_id": "NCT01331850",
      "title": "A Study of Danoprevir/Ritonavir and Copegus With RO5024048 and/or Pegasys in Patients With Chronic Hepatitis C",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Hepatitis C, Chronic"
      ],
      "interventions": [
        {
          "name": "Copegus",
          "type": "DRUG"
        },
        {
          "name": "Pegasys",
          "type": "DRUG"
        },
        {
          "name": "RO5024048",
          "type": "DRUG"
        },
        {
          "name": "danoprevir",
          "type": "DRUG"
        },
        {
          "name": "ritonavir",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Hoffmann-La Roche",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 381,
      "start_date": "2011-05",
      "completion_date": "2013-01",
      "has_results": false,
      "last_update_posted_date": "2016-11-02",
      "last_synced_at": "2026-10-02T15:25:27.395Z",
      "location_count": 19,
      "location_summary": "La Jolla, California • Long Beach, California • Sacramento, California + 15 more",
      "locations": [
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "Long Beach",
          "state": "California"
        },
        {
          "city": "Sacramento",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01331850"
    },
    {
      "nct_id": "NCT03593954",
      "title": "A Study to Assess the Effect of Ritonavir on the Single-Dose Pharmacokinetics of JNJ-61393215 in Healthy Participants",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy"
      ],
      "interventions": [
        {
          "name": "JNJ-61393215",
          "type": "DRUG"
        },
        {
          "name": "Ritonavir",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Janssen Research & Development, LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 12,
      "start_date": "2018-07-31",
      "completion_date": "2018-09-19",
      "has_results": false,
      "last_update_posted_date": "2025-04-27",
      "last_synced_at": "2026-10-02T15:25:27.395Z",
      "location_count": 1,
      "location_summary": "Salt Lake City, Utah",
      "locations": [
        {
          "city": "Salt Lake City",
          "state": "Utah"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03593954"
    },
    {
      "nct_id": "NCT05668091",
      "title": "A Decentralized, Randomized Phase 2 Efficacy and Safety Study of Nirmatrelvir/Ritonavir in Adults with Long COVID.",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Long COVID"
      ],
      "interventions": [
        {
          "name": "Nirmatrelvir",
          "type": "DRUG"
        },
        {
          "name": "Ritonavir",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Harlan M Krumholz",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 100,
      "start_date": "2023-04-14",
      "completion_date": "2024-08-21",
      "has_results": false,
      "last_update_posted_date": "2024-12-02",
      "last_synced_at": "2026-10-02T15:25:27.395Z",
      "location_count": 1,
      "location_summary": "New Haven, Connecticut",
      "locations": [
        {
          "city": "New Haven",
          "state": "Connecticut"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05668091"
    },
    {
      "nct_id": "NCT00414518",
      "title": "Safety and Effectiveness of Short-Term Anti-HIV Drug Therapy for Recent HIV-1 Infection",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "HIV Infections"
      ],
      "interventions": [
        {
          "name": "Tenofovir disoproxil fumarate/Emtricitabine",
          "type": "DRUG"
        },
        {
          "name": "Lopinavir/Ritonavir",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Colorado, Denver",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 16,
      "start_date": "2007-01",
      "completion_date": "2010-02",
      "has_results": true,
      "last_update_posted_date": "2013-02-20",
      "last_synced_at": "2026-10-02T15:25:27.395Z",
      "location_count": 2,
      "location_summary": "Denver, Colorado • Atlanta, Georgia",
      "locations": [
        {
          "city": "Denver",
          "state": "Colorado"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00414518"
    },
    {
      "nct_id": "NCT00445146",
      "title": "Safety of EVG+RTV Administered With Other Antiretroviral Agents for the Treatment of HIV-1 Infection",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "HIV Infections"
      ],
      "interventions": [
        {
          "name": "EVG",
          "type": "DRUG"
        },
        {
          "name": "RTV",
          "type": "DRUG"
        },
        {
          "name": "ARV regimen",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Gilead Sciences",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "ALL",
        "summary": "Not listed"
      },
      "enrollment_count": 192,
      "start_date": "2007-02",
      "completion_date": "2015-03",
      "has_results": true,
      "last_update_posted_date": "2016-04-25",
      "last_synced_at": "2026-10-02T15:25:27.395Z",
      "location_count": 47,
      "location_summary": "Pheonix, Arizona • Little Rock, Arkansas • Beverly Hills, California + 44 more",
      "locations": [
        {
          "city": "Pheonix",
          "state": "Arizona"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Beverly Hills",
          "state": "California"
        },
        {
          "city": "Costa Mesa",
          "state": "California"
        },
        {
          "city": "Fountain Valley",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00445146"
    },
    {
      "nct_id": "NCT01102972",
      "title": "A Simplification Study of Unboosted Reyataz With Epzicom (ASSURE)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Infection, Human Immunodeficiency Virus"
      ],
      "interventions": [
        {
          "name": "Reyataz + Norvir + Truvada",
          "type": "DRUG"
        },
        {
          "name": "Reyataz + Epzicom",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "ViiV Healthcare",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 297,
      "start_date": "2010-04",
      "completion_date": "2012-12",
      "has_results": true,
      "last_update_posted_date": "2013-11-19",
      "last_synced_at": "2026-10-02T15:25:27.395Z",
      "location_count": 44,
      "location_summary": "Hobson City, Alabama • Phoenix, Arizona • Bakersfield, California + 36 more",
      "locations": [
        {
          "city": "Hobson City",
          "state": "Alabama"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Bakersfield",
          "state": "California"
        },
        {
          "city": "Beverly Hills",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01102972"
    },
    {
      "nct_id": "NCT01418274",
      "title": "A Study to Evaluate the Effect of Danoprevir/Ritonavir on the Pharmacokinetics of Escitalopram and S-Demethylcitalopram in Healthy Volunteers",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy Volunteer"
      ],
      "interventions": [
        {
          "name": "danoprevir",
          "type": "DRUG"
        },
        {
          "name": "escitalopram",
          "type": "DRUG"
        },
        {
          "name": "ritonavir",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Hoffmann-La Roche",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 20,
      "start_date": "2011-08",
      "completion_date": "2011-09",
      "has_results": false,
      "last_update_posted_date": "2016-11-02",
      "last_synced_at": "2026-10-02T15:25:27.395Z",
      "location_count": 1,
      "location_summary": "Lenexa, Kansas",
      "locations": [
        {
          "city": "Lenexa",
          "state": "Kansas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01418274"
    }
  ]
}